Oligonucleotides and methods using same for treating cox-ll associated diseases
AssigneesKimron Veterinary Institute, Bar-llan University
InventorsMordechai Shemesh, Laurence Shore, Yehuda Stram, Shulamit Michaeli, Haim Breitbart
Life of this patent
Estimating the term…
Abstract
A small interfering duplex oligonucleotide comprising a 15 to 30 base pair sequence being at least 90 % identical to a contiguous nucleic acid sequence of COX-II, as determined using the GCG BestFit software of the Wisconsin sequence analysis package, utilizing the Smith and Waterman algorithm, where gap weight equals 50, length weight equals 3, average match equals 10 and average mismatch equals −9.
Claims146
A small interfering duplex oligonucleotide comprising a 15 to 30 base pair sequence being at least 90% identical to a contiguous nucleic acid sequence of COX-II, as determined using the GCG BestFit software of the Wisconsin sequence analysis package, utilizing the Smith and Waterman algorithm, where gap weight equals 50, length weight equals 3, average match equals 10 and average mismatch equals −9.
A method of reducing COX-II expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of COX-II specific small interfering duplex oligonucleotide, thereby reducing COX-II expression.
A method of reducing COX-II mediated prostaglandin production in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of COX-II specific small interfering duplex oligonucleotide for reducing COX-II expression, thereby reducing COX-II mediated prostaglandin production.
A method of reducing COX-II expression in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one expressible polynucleotide encoding a COX-II specific small interfering duplex oligonucleotide, thereby reducing COX-II expression.
A pharmaceutical composition for reducing COX-II-mediated prostaglandin production, the pharmaceutical composition comprising, as an active ingredient, a COX-II specific small interfering duplex oligonucleotide for reducing COX-II expression and COX-II-mediated prostaglandin production, and a pharmaceutically acceptable carrier.
A pharmaceutical composition for reducing COX-II expression, the pharmaceutical composition comprising, as an active ingredient, a COX-II specific small interfering duplex oligonucleotide selected capable of reducing COX-II expression and a pharmaceutically acceptable carrier.
Use of COX-II specific small interfering duplex oligonucleotides for the manufacture of a medicament for the treatment and/or prevention of a medical condition whereby reducing COX-II expression is beneficial.
Use of COX-II specific small interfering duplex oligonucleotides for the evaluation of a COX-II based regimen in an animal model of disease, whereby reducing COX-II expression mitigates or abolishes the onset or severity of said disease.
The use of COX-II specific small interfering duplex oligonucleotides of claim 146, wherein said prostaglandins comprise prostaglandin (PG)Gs, PGHs, PGIs, PGAs, PGBs, PGDs, PGEs and PGFs.
Dependencies are inferred from the claim text.